No Data
Immuneering's Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), NRX Pharmaceuticals (NRXP) and Immuneering (IMRX)
Immuneering to Present New Survival Data From First-Line Pancreatic Cancer Patients Treated With Atebimetinib + MGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and McKesson (MCK)
Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG) and Immuneering (IMRX)
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond